Midtown Biotech Dianthus Therapeutics Launches $625M Stock Offering to Accelerate Autoimmune Drug Pipeline

Dianthus Therapeutics, a clinical-stage biotech company headquartered in Midtown Manhattan, has announced a public stock offering valued at up to $625 million. The capital raise aims to support the development of its pipeline targeting autoimmune and inflammatory disorders, including neuropathies that result in nerve damage. The company is offering approximately 7.3 million shares priced at $81 each, with the offering expected to close by March 12.

Founded through a 2023 reverse merger with Magenta Therapeutics, Dianthus operates from its Times Square headquarters and maintains a secondary facility in Waltham, Massachusetts. The proceeds from the stock sale will fund clinical and preclinical research, commercial readiness initiatives, and general corporate purposes, positioning Dianthus to advance its drug candidates closer to market.

Despite ending 2025 with a strong cash position of $514.4 million, Dianthus reported a net loss of $162.3 million, nearly doubling from $85 million the previous year. This increase was largely driven by a 75% surge in research and development expenses, which climbed to $145.6 million amid ramped-up clinical trial activities and associated costs. The strategic investment in R&D underscores the company’s commitment to accelerating its therapeutic programs.

Dianthus’ sizable fundraising effort reflects the broader interest in biotech firms focused on autoimmune diseases, a sector marked by high unmet medical needs and significant market opportunity. Its presence in New York City’s growing life sciences ecosystem highlights Midtown’s emerging role as a hub for innovative biotech enterprises. Analysts will be watching closely to see how Dianthus deploys this capital to enhance its pipeline and commercial prospects.